Skip to main content
. 2023 Jul 12;5(10):100845. doi: 10.1016/j.jhepr.2023.100845

Fig. 5.

Fig. 5

S217879 but not elafibranor inhibits fibrogenesis.

Human PCLS were generated from the liver of patients with MAFLD (n = 12) and treated with elafibranor (10 μM) or S217879 (3 μM) or vehicle (DMSO, 0.1%) for 2 days. (A) qPCR analysis of ACTA2 expression in human PCLS. (B) Immunoblot analysis of α-SMA expression in human PCLS. (C) Immunohistochemical analysis of α-SMA-positive area (%) on human PCLS sections. Scale bar: 200 μm. (D) qPCR analysis of COL1A1 and (E) COL1A2 expression in human PCLS. Data are expressed as mean ± SEM. ∗p <0.05; ∗∗p <0.01; ns, not significant (Wilcoxon paired t test). α-SMA, alpha-smooth muscle actin; COL1A, collagen 1-alpha; MAFLD, metabolic-associated fatty liver disease; PCLS, precision cut liver slices; qPCR, quantitative PCR.